Efter markedsføring har der været indberetninger af leukopeni, trombocytopeni eller pancytopeni eller forværring af disse cytopenier hos patienter behandlet med EXJADE.
There have been post-marketing reports of leukopenia, thrombocytopenia or pancytopenia, or aggravation of these cytopenias in patients treated with EXJADE.